OpenAI launched GPT-Rosalind, a new series of AI models engineered to accelerate life sciences research. The tool assists scientists in synthesizing evidence, generating biological hypotheses, and planning experiments to bridge the gap between theory and medical progress.
The company is rolling out the model as a research preview to select customers. Early partners include biopharmaceutical giants Amgen and Moderna, alongside the nonprofit Allen Institute.
These collaborations aim to navigate complex genomics and biochemistry data to shorten drug discovery timelines.